Safety of early initiation of rivaroxaban or dabigatran after thrombolysis in acute ischemic stroke

Revue Neurologique

Volumn 171, Issue 8-9, 2015, Pages 613-615

  Ritzenthaler, T ^a,b   Derex, L ^a   Davenas, C ^a   Bnouhanna, W ^a   Farghali, A ^a   Mechtouff, L ^a   Cho, T H ^a,b   Nighoghossian, N ^a,b  

^a HÔPITAL NEUROLOGIQUE   (France)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

Acute stroke; Anticoagulants; Atrial fibrillation; Dabigatran etexilate; Rivaroxaban; Thrombolysis

Indexed keywords

CREATININE; DABIGATRAN; RIVAROXABAN; TISSUE PLASMINOGEN ACTIVATOR; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN;

AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; DRUG SAFETY; EARLY INTERVENTION; FEASIBILITY STUDY; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; GENDER; HUMAN; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; PILOT STUDY; PRESCRIPTION; PROTHROMBIN TIME; RETROSPECTIVE STUDY; THROMBIN TIME; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DRUG ADMINISTRATION; RADIOGRAPHY; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; THROMBOPHILIA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; DABIGATRAN; DRUG ADMINISTRATION SCHEDULE; FACTOR XA INHIBITORS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INTRACRANIAL HEMORRHAGES; LENGTH OF STAY; MALE; PILOT PROJECTS; RECOMBINANT PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES; RIVAROXABAN; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; THROMBOPHILIA; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84941994871     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2015.02.012     Document Type: Review

References (9)

1. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST study group. Heparin in acute embolic stroke trial. Lancet 2000;355:1205-10.
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
3. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
5. Larrue V, von Kummer RR, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian acute stroke study (ECASS II). Stroke 2001;32:438-41.
6. Jauch EC, Saver JL, Adams Jr HP, Bruno A, Connors JJB, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart association/american stroke association. Stroke 2013;44:870-947.
7. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160-236.
8. Shibazaki K, Kimura K, Aoki J, Saji N, Sakai K. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci 2013;331:90-3.
9. Harrington AR, Armstrong EP, Nolan Jr PE, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44:1676-81.